Berotec N

Berotec N

fenoterol

Manufacturer:

Boehringer Ingelheim

Distributor:

DKSH
Concise Prescribing Info
Contents
Fenoterol HBr
Indications/Uses
Symptomatic treatment of acute asthma attacks; bronchial asthma & other conditions w/ reversible airway narrowing eg, chronic obstructive bronchitis. Prophylaxis of exercise-induced asthma.
Dosage/Direction for Use
Acute asthma episodes & other conditions w/ reversible airway narrowing 1 actuation. If breathing has not improved after 5 min, a 2nd actuation may be taken. Max: 8 actuations daily. Prophylaxis of exercise-induced asthma 1-2 actuations prior to exercise. Max: 8 actuations daily. Bronchial asthma & other conditions w/ reversible airways narrowing If repeated dosing is required, 1-2 puffs to be given each time. Max: 8 puffs daily.
Contraindications
Hypersensitivity. Hypertrophic obstructive cardiomyopathy; tachyarrhythmia.
Special Precautions
Discontinue use if paradoxical bronchospasm occurs. Patients w/ underlying severe heart disease eg, ischaemic heart disease, arrhythmia or severe heart failure; acute, rapidly worsening dyspnea; insufficiently controlled DM; recent MI; severe organic heart or vascular disorders; hyperthyroidism; phaeochromocytoma; hypokalaemia. Positive doping test result. Concomitant use w/ xanthine derivatives, glucocorticosteroids, diuretics; sympathomimetic & anticholinergic bronchodilators. May affect ability to drive & use machines. Pregnancy & lactation.
Adverse Reactions
Hypersensitivity; hypokalaemia; agitation, nervousness; tremor, headache, dizziness; myocardial ischaemia, arrhythmia, tachycardia, palpitations; paradoxical bronchospasm, cough, throat irritation; nausea, vomiting; hyperhidrosis, skin reaction eg, rash, pruritus, urticaria; muscle spasm, myalgia, muscular weakness; increased systolic BP, decreased diastolic BP.
Drug Interactions
Enhanced effects by β-adrenergics, anticholinergics, xanthine derivatives eg, theophylline. Increased β2-agonist induced hypokalaemia w/ corticosteroids, diuretics. Potentially serious reduction in bronchodilatation w/ β-blockers. Enhanced β-adrenergic agonists action w/ MAOIs or TCAs. Increased susceptibility to CV effects of β-agonists w/ halogenated hydrocarbon anaesth eg, halothane, trichloroethylene, enflurane.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03AC04 - fenoterol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Berotec N MDI 100 mcg/puff
Packing/Price
200 puff x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in